Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.

Exclusion Criteria

• •Previous treatment with ≥2 lines of systemic therapy for metastatic disease;
• •Symptomatic peripheral neuropathy ≥2 grades according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03;
• •Uncontrolled infections in active phase, disseminated intravascular coagulation in activity;
• •Clinically significant cardiovascular disease, such as cardiovascular accidents (less than 6 months after initiation of treatment), myocardial infarction (less than 6 months after initiation of treatment), unstable angina, chronic heart failure ≥2 New York Heart Association (NYHA) grade, uncontrolled arrhythmias;
• •Past (within 2 years of treatment initiation, except for curatively treated basal or squamous cell carcinomas of the skin or carcinoma in situ of the cervix) or current history of malignancy other than gastric cancer.